Discovery of potent CRTh2 (DP2) receptor antagonists

  • Bioorg Med Chem Lett. 2006 Aug 15;16(16):4287-90. doi: 10.1016/j.bmcl.2006.05.062.
Timothy N Birkinshaw  1 ,  Simon J Teague ,  Claire Beech ,  Roger V Bonnert ,  Stephen Hill ,  Anil Patel ,  Sara Reakes ,  Hitesh Sanganee ,  Iain G Dougall ,  Tim T Phillips ,  Sylvia Salter ,  Jerzy Schmidt ,  Elizabeth C Arrowsmith ,  Juan J Carrillo ,  Fiona M Bell ,  Stuart W Paine ,  Richard Weaver
Affiliations
  • 1. Department of Medicinal Chemistry, AstraZeneca R&D Charnwood, Loughborough, UK. [email protected]
PMID: 16753296 DOI: 10.1016/j.bmcl.2006.05.062
Abstract

Starting with the weak agonist indomethacin, a series of potent, selective CRTh2 (DP(2)) antagonists have been discovered as potential treatments for asthma, allergic rhinitis and Other inflammatory diseases.

Products